PD-L1 Low Expression (TPS = 1-49.999%) is an inclusion criterion in 7 clinical trials for non-small cell lung carcinoma, of which 7 are open and 0 are closed. Of the trials that contain PD-L1 Low Expression (TPS = 1-49.999%) and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 4 are phase 2 (4 open) [5].

PD-L1 Low Expression (TPS = 1-49.999%) is an inclusion criterion in 5 clinical trials for squamous cell lung carcinoma, of which 4 are open and 1 is closed. Of the trials that contain PD-L1 Low Expression (TPS = 1-49.999%) and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 3 are phase 2 (3 open) [5].

PD-L1 Low Expression (TPS = 1-49.999%) is an inclusion criterion in 4 clinical trials for malignant solid tumor, of which 3 are open and 1 is closed. Of the trials that contain PD-L1 Low Expression (TPS = 1-49.999%) and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 1/phase 2 (2 open) [5].

PD-L1 Low Expression (TPS = 1-49.999%) is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PD-L1 Low Expression (TPS = 1-49.999%) and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

PD-L1 Low Expression (TPS = 1-49.999%) is an inclusion criterion in 2 clinical trials for lung adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain PD-L1 Low Expression (TPS = 1-49.999%) and lung adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

PD-L1 Low Expression (TPS = 1-49.999%) is an inclusion criterion in 2 clinical trials for non-squamous non-small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PD-L1 Low Expression (TPS = 1-49.999%) and non-squamous non-small cell lung carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

PD-L1 Low Expression (TPS = 1-49.999%) is an inclusion criterion in 2 clinical trials for urothelial carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PD-L1 Low Expression (TPS = 1-49.999%) and urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [5].

PD-L1 Low Expression (TPS = 1-49.999%) is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 Low Expression (TPS = 1-49.999%) and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) [5].

PD-L1 Low Expression (TPS = 1-49.999%) is an inclusion criterion in 1 clinical trial for ampulla of vater carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PD-L1 Low Expression (TPS = 1-49.999%) and ampulla of vater carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

PD-L1 Low Expression (TPS = 1-49.999%) is an inclusion criterion in 1 clinical trial for bladder urothelial carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PD-L1 Low Expression (TPS = 1-49.999%) and bladder urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

PD-L1 Low Expression (TPS = 1-49.999%) is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains PD-L1 Low Expression (TPS = 1-49.999%) and cholangiocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

PD-L1 Low Expression (TPS = 1-49.999%) is an inclusion criterion in 1 clinical trial for distal bile duct carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PD-L1 Low Expression (TPS = 1-49.999%) and distal bile duct carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

PD-L1 Low Expression (TPS = 1-49.999%) is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PD-L1 Low Expression (TPS = 1-49.999%) and gallbladder carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

PD-L1 Low Expression (TPS = 1-49.999%) is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 Low Expression (TPS = 1-49.999%) and gastric adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PD-L1 Low Expression (TPS = 1-49.999%) is an inclusion criterion in 1 clinical trial for infiltrating renal pelvis and ureter urothelial carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PD-L1 Low Expression (TPS = 1-49.999%) and infiltrating renal pelvis and ureter urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

PD-L1 Low Expression (TPS = 1-49.999%) is an inclusion criterion in 1 clinical trial for intrahepatic cholangiocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains PD-L1 Low Expression (TPS = 1-49.999%) and intrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

PD-L1 Low Expression (TPS = 1-49.999%) is an inclusion criterion in 1 clinical trial for large cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 Low Expression (TPS = 1-49.999%) and large cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PD-L1 Low Expression (TPS = 1-49.999%) is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 Low Expression (TPS = 1-49.999%) and lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PD-L1 Low Expression (TPS = 1-49.999%) is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 Low Expression (TPS = 1-49.999%) and renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PD-L1 Low Expression (TPS = 1-49.999%) is an inclusion criterion in 1 clinical trial for renal pelvis urothelial carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PD-L1 Low Expression (TPS = 1-49.999%) and renal pelvis urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

PD-L1 Low Expression (TPS = 1-49.999%) is an inclusion criterion in 1 clinical trial for ureter urothelial carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PD-L1 Low Expression (TPS = 1-49.999%) and ureter urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

PD-L1 Low Expression (TPS = 1-49.999%) is an inclusion criterion in 1 clinical trial for urethral urothelial carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PD-L1 Low Expression (TPS = 1-49.999%) and urethral urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].